GDTC Stock Catalyst: CytoMed Therapeutics Signs Collaboration Agreement with SunAct Cancer Institute for Phase 2 Clinical Trial

Jan 6, 2025 · 7:01am ET

Agreement aims to advance treatment of solid cancers using Gamma Delta T Cells.

Max move

+127.2%

High of day $7.93

Sparker timei

7:01am ET

GDTC · Jan 6, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

CytoMed Therapeutics Ltd (Nasdaq: GDTC) and SunAct Cancer Institute Private Limited announced on January 6, 2025, the signing of a Business & Research Collaboration Agreement. The agreement focuses on advancing the use of allogeneic off-the-shelf Gamma Delta T Cells for the treatment of solid cancers in a proposed Phase 2 clinical trial in India.

The collaboration will leverage CytoMed's expertise in cell therapy and SunAct's clinical research capabilities to explore the potential of Gamma Delta T Cells in oncology. The trial aims to evaluate the safety and efficacy of this innovative approach in treating solid tumors.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GDTC sparks.

Download Sniper App →

Catch the next GDTC-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →